Terminate R788 Problems Definately

Patients�� satisfaction with the cosmetic result of the procedure (based on the Verbal Rating Scale (VRS); 0 �C poor, 1 �C weak, 2 �C satisfactory, 3 �C good, 4 �C very good, 5 �C excellent) including scar length and healing was assessed at 1, 6 and 12 months postoperatively during outpatient follow-up visits. Cost analysis was performed using an official in-hospital price list for medical procedures. The costs included (in EUR): 20 EUR for ultrasonography, 200 EUR for sestamibi scintigraphy, 100 EUR for IOPTH, 5 EUR/min for anaesthesia, 5 EUR/min for operating theatre use, 5 EUR/min for videoscopic equipment, and 80 EUR/day of hospitalisation. Statistical analysis For sample size calculation, an assumption was made that MIVAP should result in pain intensity lower by 30% as compared to OMIP. To detect this, it was calculated that 124 patients would be required in each treatment arm to give the study a power of 95%. Anticipating Cisplatin a 15% loss to follow-up, 150 patients per arm were required in the study. Data are presented as mean with standard deviation (SD) or range, unless stated otherwise. The statistical significance of categorical variables was evaluated by the ��2 test, whereas Student's t test was used for analysis of continuous variables. Receiver operating characteristics (ROC) were R788 used to evaluate the diagnostic accuracy of IOPTH in prognostication of cure of the hyperparathyroid state. All the data were collected prospectively and stored in a computer-based institutional Calcitriol concentration register of parathyroid surgery and analysed retrospectively by a statistician. Statistical analyses were performed with MedCalc (version 13, MedCalc Software, Belgium). Value of p 17; lithium treatment 12; lacking consent for MIP 5; MEN 2A syndrome 5), and 8 had incomplete histopathology or follow-up data, leaving 455 patients who were finally included in this study. One-hundred and fifty-one patients underwent MIVAP, whereas 304 patients underwent OMIP. There were 398 women and 57 men with a mean age at operation of 55.7 ��16.1 years (range: 18�C82). Analysis of baseline characteristics identified that MIVAP patients were significantly younger (51.7 ��14.9 years vs. 57.7 ��16.3 years, respectively; p